Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

prnewswire.com
BMY Bristol-Myers Squibb's SOTYKTU is highlighted as an emerging therapy for juvenile idiopathic arthritis, representing a new category of small-molecule treatments with a unique allosteric mechanism. The drug's precise targeting and favorable efficacy are expected to drive market growth. ABBV AbbVie is listed as a key company in the juvenile idiopathic arthritis market. Their drug RINVOQ is mentioned as a marketed therapy, but specific details on its performance or future outlook within this market are not elaborated upon in the article. REGN Regeneron Pharmaceuticals is mentioned as a key company in the juvenile idiopathic arthritis market, specifically in relation to the drug KEVZARA (co-developed with Sanofi). The article does not provide specific sentiment or detailed analysis for Regeneron's performance in this particular market. LLY Eli Lilly is listed as a key company in the juvenile idiopathic arthritis market. Their drugs OLUMIANT and TALTZ are mentioned, but the article does not provide specific sentiment or detailed analysis regarding their performance or future prospects in this market. PFE Pfizer is listed as a key company in the juvenile idiopathic arthritis market. Their drug XELJANZ is mentioned, but the article does not provide specific sentiment or detailed analysis regarding its performance or future prospects in this market.

The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others will further propel the market forward.

LAS VEGAS, Feb. 17, 2026 /PRNewswire/ -- Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Juvenile Idiopathic Arthritis Market Summary

Discover which regions are driving the fastest JIA market growth @ https://www.delveinsight.com/sample-request/juvenile-idiopathic-arthritis-jia-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the Growth of the Juvenile Idiopathic Arthritis Market

Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, said that the JIA market is evolving as treatment focus shifts from broad-spectrum biologics to more targeted therapies, with JAK inhibitors and IL-targeted agents driving adoption due to their favorable efficacy, safety, and expanded pediatric indications.

Juvenile Idiopathic Arthritis Market Analysis

Juvenile Idiopathic Arthritis Competitive Landscape

Some of the JIA drugs in the clinical trial landscape include SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others.

Bristol-Myers Squibb's SOTYKTU is an oral, highly selective TYK2 inhibitor that works through a unique allosteric mechanism, marking it as part of a new category of small-molecule treatments. It is the first therapy of its kind to undergo clinical evaluation across several immune-mediated conditions. Developed by Bristol Myers Squibb, the drug is engineered to precisely target TYK2 and block signaling driven by IL-23, IL-12, and type I interferons, pathways that are central to many immune-related diseases. Its strong selectivity comes from binding to TYK2's regulatory domain, leading to allosteric suppression of TYK2 function and its downstream signals. At levels relevant to treatment, it inhibits TYK2 specifically without affecting JAK1, JAK2, or JAK3.

UCB Biopharma's Bimekizumab is a humanized IgG1 monoclonal antibody designed to selectively neutralize both IL-17A and IL-17F, two cytokines that play major roles in driving inflammation. Currently, the drug is in phase III clinical trials.

The anticipated launch of these emerging therapies are poised to transform the juvenile idiopathic arthritis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the juvenile idiopathic arthritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about which new or emerging therapies are expected to shape the JIA market @ Juvenile Idiopathic Arthritis Drugs

Recent Developments in the Juvenile Idiopathic Arthritis Market

What is Juvenile Idiopathic Arthritis?

Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition that causes persistent joint inflammation in children and adolescents, typically under the age of 16. In JIA, the immune system mistakenly attacks the body's own tissues, leading to symptoms such as joint pain, swelling, stiffness, and reduced mobility. These symptoms can vary from mild to severe and may affect one joint or multiple joints. Although the exact cause is unknown, a combination of genetic and environmental factors is likely contributing. Early diagnosis and treatment are important for managing symptoms, preventing joint damage, and supporting healthy growth and development.

Juvenile Idiopathic Arthritis Epidemiology Segmentation

The juvenile idiopathic arthritis epidemiology section provides insights into the historical and current juvenile idiopathic arthritis patient pool and forecasted trends for the leading markets. In the US, approximately 34K diagnosed JIA patients in 2025 were male, whereas 66% female. This sex difference is attributed to females' greater susceptibility to developing JIA, whereas the onset in males tends to occur later.

The juvenile idiopathic arthritis treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

Juvenile Idiopathic Arthritis Market Report Metrics

Details

Study Period

2022–2036

Coverage

7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Juvenile Idiopathic Arthritis Market CAGR

5.6 %

Juvenile Idiopathic Arthritis Market Size in 2025

USD 2.3 Billion

Key Juvenile Idiopathic Arthritis Companies

Bristol-Myers Squibb (NYSE: BMY), UCB Biopharma (EBR: UCB), Novartis (SWX: NOVN), AbbVie (NYSE: ABBV), Sanofi (EPA: SAN), Regeneron Pharmaceuticals (NASDAQ: REGN), Janssen Pharmaceutical, Eli Lilly (NYSE: LLY), Sobi (STO: SOBI), Pfizer (NYSE: PFE), and others

Key Juvenile Idiopathic Arthritis Therapies

Deucravacitinib (SOTYKTU), Bimekizumab (BIMZELX), MAS825, RINVOQ, KEVZARA, TREMFYA, COSENTYX, ORENCIA, CIMZIA, ILARIS, SIMPONI ARIA, OLUMIANT, TALTZ, KINERET, XELJANZ, and others

Scope of the Juvenile Idiopathic Arthritis Market Report

Download the report to understand who are the top pharmaceutical companies in juvenile idiopathic arthritis @ Juvenile Idiopathic Arthritis Market Analysis

Table of Contents

1

Juvenile Idiopathic Arthritis Market Key Insights

2

Juvenile Idiopathic Arthritis Market Report Introduction

3

Executive Summary

4

Key Events

5

Epidemiology and Market Forecast Methodology

6

JIA Market Overview at a Glance

6.1

Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)

6.2

Market Share (%) Distribution of JIA By Therapies in the 7MM, in 2025

6.3

Market Share (%) Distribution of JIA By Therapies in the 7MM, in 2036

7

Disease Background and Overview

7.1

Introduction

7.2

Types

7.3

Symptoms

7.4

Causes

7.5

Pathophysiology

7.6

Diagnosis

7.7

Treatment

8

Treatment Guidelines

9

Epidemiology and Patient Population

9.1

Key Findings

9.2

Assumptions and Rationale

9.3

Diagnosed Prevalent Cases of JIA in the 7MM

9.4

The United States

9.4.1

Total Diagnosed Prevalent Cases of JIA in the United States

9.4.2

Subtype-specific Diagnosed Prevalent Cases of JIA in the United States

9.4.3

Gender-specific Diagnosed Prevalent Cases of JIA in the United States

9.4.4

Treatment Eligible Cases of JIA in the United States

9.5

EU4 and the UK

9.6

Japan

10

Juvenile Idiopathic Arthritis Patient Journey

11

Marketed Juvenile Idiopathic Arthritis Therapies

11.1

Key Cross Competition

11.2

Upadacitinib (RINVOQ): AbbVie

11.2.1

Drug Description

11.2.2

Regulatory Milestones

11.2.3

Other Developmental Activities

11.2.4

Summary of Pivotal Trials

11.2.5

Clinical Development

11.2.5.1

Clinical Trial Information

11.2.6

Analyst Views

11.3

Sarilumab (KEVZARA): Sanofi/Regeneron Pharmaceuticals

11.4

Guselkumab (TREMFYA): Janssen Pharmaceutical

11.5

Secukinumab (COSENTYX): Novartis

11.6

Abatacept (ORENCIA): Bristol-Myers Squibb

11.7

Certolizumab pegol (CIMZIA): UCB Biopharma

11.8

Canakinumab (ILARIS): Novartis

11.9

Golimumab (SIMPONI ARIA): Janssen Pharmaceutical

11.1

Baricitinib (OLUMIANT): Eli Lilly

11.11

Ixekizumab (TALTZ): Eli Lilly

11.12

Anakinra (KINERET): Sobi

11.13

Tofacitinib (XELJANZ): Pfizer

12

Emerging Juvenile Idiopathic Arthritis Drugs

12.1

Key Cross Competition

12.2

Deucravacitinib (SOTYKTU): Bristol-Myers Squibb

12.2.1

Drug Description

12.2.2

Other Developmental Activities

12.2.3

Clinical Development

12.2.3.1

Clinical Trials Information

12.2.4

Analyst Views

12.3

Bimekizumab (BIMZELX): UCB

12.4

MAS825: NOVARTIS

13

JIA Market: 7MM Analysis

13.1

Key Findings

13.2

Juvenile Idiopathic Arthritis Market Outlook

13.3

Key Juvenile Idiopathic Arthritis Market Forecast Assumptions

13.4

Conjoint Analysis

13.5

Total Market Size of JIA in the 7MM

13.6

Total Market Size of JIA by Therapies in the 7MM

13.7

The United States Juvenile Idiopathic Arthritis Market

13.7.1

Total Market Size of JIA in the United States

13.7.2

Total Market Size of JIA by Therapies in the United States

13.8

EU4 and the UK Juvenile Idiopathic Arthritis Market

13.9

Japan Juvenile Idiopathic Arthritis Market

14

Juvenile Idiopathic Arthritis Market Unmet Needs

15

Juvenile Idiopathic Arthritis Market SWOT Analysis

16

KOL Views on JIA

17

Juvenile Idiopathic Arthritis Market Access and Reimbursement

17.1

The United States

17.2

EU4 and the UK

17.3

Japan

17.4

Summary and comparison of Market Access and Pricing Policy Developments in 2025

17.5

Market Access and Reimbursement of JIA Therapies

18

Bibliography

19

Juvenile Idiopathic Arthritis Market Report Methodology

Related Reports

Juvenile Idiopathic Arthritis Clinical Trial Analysis

Juvenile Idiopathic Arthritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JIA companies, including Bristol-Myers Squibb, UCB Biopharma, Novartis, AbbVie, Sanofi, Regeneron Pharmaceuticals, Janssen Pharmaceutical, Eli Lilly, Sobi, Pfizer, and others.

Systemic Juvenile Idiopathic Arthritis Market

Systemic Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key systemic juvenile idiopathic arthritis companies including Novartis, Roche, Genentech, AbbVie, Pfizer, Eli Lilly and Company, Bristol Myers Squibb, Johnson & Johnson, Merck & Co., UCB, Sanofi, and others.

Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies including Cyxone, Taiho Pharmaceutical, AstraZeneca, Eli Lilly and Company, Rise Therapeutics, TNF Pharmaceuticals, Incyte, UCB, and others.

Axial Spondyloarthritis Market

Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key axial spondyloarthritis companies including Janssen Pharmaceuticals, Pfizer, UCB, Amgen, Kyowa Kirin, Eli Lilly and Company, Novartis, AbbVie, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

[email protected]

+14699457679

www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP